Editorial: Extracellular matrix in homeostasis and cancer

Editorial on the Research Topic
Extracellular matrix in homeostasis and cancer

Organs are composed not only of a variety of cells, but also of extracellular matrices (ECMs), which provide a physical scaffold and specialized microenvironment for cells and tissues, and allow biochemical signaling. Particularly since the 1970s, the ECM started to be recognized as a highly dynamic component of tissues and the importance of ECM remodeling was found to play an important role in embryonic development, tissue repair and regeneration. In addition to the key ECM components, namely collagens, laminins, fibronectin, elastin, hyaluronan and proteoglycans, our current understanding of ECM dynamics and its tissue specificity allowed us to expand the list of ECM components, collectively termed the matrisome (Naba et al., 2012). In addition to these “core” components (around 300 in mammals), there is a variety of ECM-related molecules, which include proteins required for ECM remodeling, cytokines, chemokines and growth factors, together revealing the dynamic nature of the ECM.

For this Research Topic, we thought of bringing together contributions on how the ECM plays a critical role in tissue homeostasis and disease, with special emphasis on how ECM remodeling and mutations contribute to cancer.

In recognition of the key importance of ECM in tissue development and homeostasis, there are emerging studies using in vitro three-dimensional models, where the ECM composition and structure directly impacts cell proliferation, migration, differentiation or survival, mimicking in vivo conditions. In keeping with this notion, Carvalho and others have shown that ECM is able to modulate proliferation of mesenchymal stromal cells (MSC), a multipotent stem/progenitor cell population capable of proliferating and differentiating into a variety of lineages, such as adipogenic, chondrogenic, and osteogenic (Carvalho et al.). Moreover, the authors show that ECM derived from young donors was able to rescue the impaired proliferative and osteogenic potential of aged MSC, therefore highlighting the importance of ECM composition and its potential for therapeutic intervention.

Considering the key role of ECM in maintaining tissue integrity, and promoting tissue repair and regeneration, it is not surprising that when the composition of ECM is altered, for example due to mutations or changes in the levels of ECM components this can also lead to diseases. These changes in the levels of ECM components may be triggered by several endogenous and exogenous insults, that can promote increased oxidative stress and DNA damage, as reviewed by Martins el al. In this review, the authors go over how DNA damage and oxidative stress affect the expression and deposition of ECM molecules, and conversely how mutations in the genes that code for ECM components cause an increase in DNA damage and oxidative (Martins et al.). Both circumstances make it challenging for cells and tissues to return to a state of homeostasis, which has an adverse effect on organ and tissue function and may be a trigger for several disorders. An example of these disorders includes cancer, in which cancer cells manipulate a number of elements involved in ECM remodeling to serve their own purposes, promoting cancer cell migration, proliferation, and epithelial-to-mesenchymal transition. In accordance, several studies have revealed the potential of using ECM and associated components as prognostic signatures for different types of cancer. This is the case of CTHRC1 (collagen triple helix repeat containing 1) and LRFN4 (leucine rich repeat and fibronectin type III domain containing 4), as prognostic signature in stomach adenocarcinoma (Han et al.), COL4A6 (collagen IV alpha six chain), FGA (fibrinogen alpha chain) and FSCN1 (fascin actin-bundling protein 1), as potential biomarkers for lung adenocarcinoma (Zeng et al.) or FN1 (fibronectin), LAMB4 (laminin beta four chain), LAMB3 (laminin beta three chain), DMP1 (dentin matrix acidic phosphoprotein 1), CHAD (chondroadherin), and MMRN1 (multimerin 1, also called elastin microfibril interfacer 4), as a matrisome-related gene signature of head and neck squamous cell carcinoma (Huang et al.).

Altogether these findings stress how crucial ECM is for preserving tissue homeostasis. Improving our understanding regarding the matrisome and other ECM-related molecules will be critical to improve therapeutic strategies in cancer. In addition, and considering that mutations in genes that encode ECM components have been linked to a variety of genetic disorders, such as different neuromuscular diseases, neurodegenerative diseases, Ehlers Danlos Syndromes, and osteogenesis imperfecta, this knowledge will have a wide clinical application.

Author contributions

ARC and VA wrote and discussed the editorial.

Funding

ARC was supported by Fundação para a Ciência e Tecnologia (FCT, Portugal; CEECIND/01589/2017 and PTDC/BTM-ORG/1383/2020); L’Oréal Portugal Medals of Honor for Women in Science 2019; Unit Funding (Ref. UIDB/00329/2020); the generosity of the donor Henrique Meirelles, who chose to support the MATRIHEALTH Project. VA was supported by INSERM (Institut National de la Santé et de la Recherche Médicale) and by Stiftelserna Crafoord and Wenner-Gren.

Acknowledgments

The guest editors would like to express their gratitude to all contributors and reviewers for their important work on this Research Topic. We also hope that the medical and genetics communities will find this Research Topic to be of interest.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Reference

Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., and Hynes, R. O. (2012). The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteomics 11, M111.014647. doi:10.1074/MCP.M111.014647

PubMed Abstract | CrossRef Full Text | Google Scholar